EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 35 / No 12 (Décembre 2019) Med Sci (Paris), 35 12 (2019) 937-945 References
Open Access
Issue
Med Sci (Paris)
Volume 35, Number 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
Page(s) 937 - 945
Section La révolution des anticorps modulateurs de la réponse immunitaire en oncologie
DOI https://doi.org/10.1051/medsci/2019225
Published online 06 January 2020
  1. Fridman WH. Historique de l’immunothérapie. Changement de paradigme ? Bull Cancer (Paris) 2016; 103: S122–6. [CrossRef] [Google Scholar]
  2. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008 ; 26: 527–534. [CrossRef] [PubMed] [Google Scholar]
  3. Gregor RT. Vitiligo and malignant melanoma: a significant association?. South Afr Med J 1976 ; 50: 1447–1449. [Google Scholar]
  4. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011 ; 364: 2517–2526. [Google Scholar]
  5. Maio M, Grob J-J, Aamdal S, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 2015 ; 33: 1191–1196. [CrossRef] [PubMed] [Google Scholar]
  6. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015 ; 372: 320–330. [Google Scholar]
  7. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015 ; 372: 2521–2532. [Google Scholar]
  8. Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (Keynote-006). Lancet 2017 ; 390: 1853–1862. [CrossRef] [PubMed] [Google Scholar]
  9. Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 2018 ; 19: 1480–1492. [CrossRef] [PubMed] [Google Scholar]
  10. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant Pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 2018 ; 378: 1789–1801. [Google Scholar]
  11. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017 ; 377: 1824–1835. [Google Scholar]
  12. Amaria RN, Reddy SM, Tawbi HA, et al. Publisher correction: neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 2018 ; 24: 1942. [Google Scholar]
  13. Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: non–small cell lung cancer, version 4.2016. J Natl Compr Canc Netw 2016 ; 14: 255–264. [Google Scholar]
  14. Duruisseaux M, Berghmans T. Évolution et révolution dans la prise en charge systémique des cancers du poumon. La nouvelle place des immunothérapies. Rev Mal Respir 2018 ; 35: 101–102. [CrossRef] [PubMed] [Google Scholar]
  15. OPDIVO: indications en France en août 2019. Paris: ANSM, 2019. [Google Scholar]
  16. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015 ; 373: 123–135. [Google Scholar]
  17. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015 ; 373: 1627–1639. [Google Scholar]
  18. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017 ; 389: 255–265. [CrossRef] [PubMed] [Google Scholar]
  19. Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (Keynote-010): a randomised controlled trial. Lancet 2016 ; 387: 1540–1550. [CrossRef] [PubMed] [Google Scholar]
  20. KEYTRUDA: indications en France en juin 2019. Paris: ANSM, 2019. [Google Scholar]
  21. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med 2016 ; 375: 1823–1833. [Google Scholar]
  22. Lopes G, Wu Y-L, Kudaba I, et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 Keynote-042 study. J Clin Oncol 2018; 36: LBA4. [Google Scholar]
  23. Jimenez Alguilar E, Gainor J, Kravets S, et al. MA04.05 outcomes in NSCLC patients treated with first-line pembrolizumab and a PD-L1 TPS of 50–74% vs 75–100% or 50–89% vs 90–100%. J Thorac Oncol 2018; 13: S367–8. [Google Scholar]
  24. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N Engl J Med 2018 ; 379: 2040–2051. [Google Scholar]
  25. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med 2018 ; 378: 2078–2092. [Google Scholar]
  26. Jotte RM, Cappuzzo F, Vynnychenko I, et al. IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. J Clin Oncol 2018; 36: LBA9000. [Google Scholar]
  27. WCLC 2018. IMpower132: Atezolizumab plus carboplatin and pemetrexed in stage IV nonsquamous NSCLC. The ASCO Post, 2019. [Google Scholar]
  28. TECENTRIQ: indications en Europe en août 2019. Amsterdam: European Medicines Agency, 2019. [Google Scholar]
  29. Ryu R, Ward KE. Atezolizumab for the first-line treatment of non-small cell lung cancer (NSCLC): current status and future prospects. Front Oncol 2018; 8. [Google Scholar]
  30. Socinski MA, Jotte RM, Cappuzzo F, et al. Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. J Clin Oncol 2018 ; 36: 9002. [Google Scholar]
  31. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018 ; 378: 2288–2301. [Google Scholar]
  32. Hellmann MD, Ciuleanu T-E, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 2018 ; 378: 2093–2104. [Google Scholar]
  33. IMFIZI: indications en Europe en août 2019. Amsterdam: European Medicines Agency, 2018. [Google Scholar]
  34. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018 ; 379: 2342–2350. [Google Scholar]
  35. Horn L, Mansfield AS, Szcze˛sna A, et al. First-line Atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018 ; 379: 2220–2229. [Google Scholar]
  36. Alley EW, Katz SI, Cengel KA, et al. Immunotherapy and radiation therapy for malignant pleural mesothelioma. Transl Lung Cancer Res 2017 ; 6: 212–219. [CrossRef] [PubMed] [Google Scholar]
  37. Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol 2019 ; 20: 239–253. [CrossRef] [PubMed] [Google Scholar]
  38. Forde PM, Scherpereel A, Tsao AS. Use of Immune Checkpoint Inhibitors in Mesothelioma. Curr Treat Options Oncol 2019 ; 20: 18. [CrossRef] [PubMed] [Google Scholar]
  39. Ettinger DS, Aisner DL, Wood DE, et al. NCCN guidelines insights: non-small cell lung cancer, version 5.2018. J Natl Compr Canc Netw 2018 ; 16: 807–821. [Google Scholar]
  40. Scherpereel A, Wallyn F, Albelda SM, et al. Novel therapies for malignant pleural mesothelioma. Lancet Oncol 2018 ; 19: e161–e172. [CrossRef] [PubMed] [Google Scholar]
  41. Fridman WH, Teillaud JL. De la traversée du désert au prix Nobel de Physiologie ou Médecine décerné à James Allison et Tasuku Honjo: la longue marche de l’immunothérapie des cancers - Entretien avec Wolf Hervé Fridman. Med Sci (Paris) 2019 ; 35: 367–373. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.